Compounded-product advertising is not a sufficient basis for including a route in the procurement base case. FDA’s April 1, 2026 policy update states that semaglutide and tirzepatide are not on its shortage list or 503B bulks list. It also explains restrictions on essentially copying commercially available products, including circumstances involving added vitamin B12. The page was checked November 17, 2026. FDA policy update (fda.gov)
On April 30, 2026, FDA separately announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. The cited announcement is a proposal, not a final determination. This research does not assert that every later docket or litigation development has been resolved. FDA proposal
Accordingly, this report does not publish a standardized “lawful compounded GLP-1 wholesale price range.” A patient-specific prescription, facility registration or formulation change should not be treated as automatic permission; the actual arrangement requires product-specific legal and clinical review. FDA’s conditions and distinctions
Recent clinical-process watch item: FDA issued a safety communication on November 9, 2026 requiring labeling changes concerning a potential increased risk of the rare eye condition NAION. Procurement teams should refer this to clinical leadership and request confirmation that partner communications and escalation processes remain current—not independently redesign treatment. FDA safety communication
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- fda.gov · Source 2 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential